Payment overview · 2025
General Payments
$367.91
18 reported records · 10 companies
Healthcare provider profile · identity verified
John B Sissney, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DENISON, TX · NPI 1154681401
Verified facts
What the public records show
CMS Open Payments records show John B Sissney, D.O. received $367.91 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.17 | 37.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.59 | 10.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.36 | 10.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.10 | 10.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.33 | 7.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.83 | 6.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19.12 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.52 | 4.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.10 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.79 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $367.91 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.46 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.33 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 267 | 71 |
| Montelukast Sodium | Montelukast Sodium | 244 | 76 |
| Furosemide | Furosemide | 241 | 70 |
| Gabapentin | Gabapentin | 232 | 63 |
| Lisinopril | Lisinopril | 230 | 58 |
| Potassium Chloride | Potassium Chloride | 204 | 50 |
| Losartan Potassium | Losartan Potassium | 197 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 50 |
| Dexamethasone | Dexamethasone | 159 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 43 |
| Metformin Hcl | Metformin Hcl | 147 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 37 |
| Simvastatin | Simvastatin | 144 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 79 |
| Omeprazole | Omeprazole | 136 | 33 |
| Eliquis | Apixaban | 130 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 47 |
| Methylprednisolone | Methylprednisolone | 126 | 101 |
| Tramadol Hcl | Tramadol Hcl | 122 | 47 |
| Indomethacin | Indomethacin | 119 | 45 |
| Alprazolam | Alprazolam | 118 | 34 |
| Prednisone | Prednisone | 111 | 54 |
| Meloxicam | Meloxicam | 109 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 33 |
| Ozempic | Semaglutide | 101 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 80 |
| Glimepiride | Glimepiride | 98 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 31 |
| Trazodone Hcl | Trazodone Hcl | 94 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 29 |
| Bupropion Xl | Bupropion Hcl | 80 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 77 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 76 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 53 |
| Buspirone Hcl | Buspirone Hcl | 69 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 16 |
| Carvedilol | Carvedilol | 57 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | 12 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Jardiance | Empagliflozin | 51 | 11 |
| Doxepin Hcl | Doxepin Hcl | 50 | 15 |
| Finasteride | Finasteride | 50 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 13 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 15 |
| Azithromycin | Azithromycin | 45 | 42 |
| Celecoxib | Celecoxib | 45 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Allopurinol | Allopurinol | 42 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 17 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 40 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 23 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | 11 |
| Pregabalin | Pregabalin | 37 | 15 |
| Sertraline Hcl | Sertraline Hcl | 37 | 11 |
| Atenolol | Atenolol | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Temazepam | Temazepam | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 18 |
| Sucralfate | Sucralfate | 29 | 11 |
| Cefdinir | Cefdinir | 28 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Lorazepam | Lorazepam | 28 | 14 |
| Topiramate | Topiramate | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 20 |
| Estradiol | Estradiol | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Linzess | Linaclotide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 13 |
| Diazepam | Diazepam | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | 11 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Oxtellar Xr | Oxcarbazepine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $367.91 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, REPATHA, TRELEGY ELLIPTA, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error